Search Results for "Eliquis"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Eliquis. Results 1 to 4 of 4 total matches.
See also: apixaban
Comparison Table: Some Oral Anticoagulants for VTE (online only)
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022 (Issue 1655)
Interactions Comments Cost2
Factor Xa Inhibitors
Apixaban – Eliquis (BMS) Prophylaxis of DVT
following hip ...
View the Comparison Table: Some Oral Anticoagulants for VTE
Balfaxar: Another Four-Factor PCC for Warfarin Reversal
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
) is available for reversal
of the anticoagulant effects of rivaroxaban (Xarelto)
and apixaban (Eliquis ...
Balfaxar (Octapharma), a human plasma-derived
four-factor prothrombin complex concentrate (PCC),
has been approved by the FDA for rapid reversal of
warfarin anticoagulation in adults who require an
urgent surgical/invasive procedure. It is the second
four-factor PCC to become available in the US;
Kcentra, which has been available since 2013, is
approved for the same indication and for urgent
reversal of warfarin anticoagulation in adults with
acute major bleeding. Balfaxar is marketed in Canada
and Europe as Octaplex.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):31-2 doi:10.58347/tml.2024.1696d | Show Introduction Hide Introduction
Drugs for Treatment and Prevention of Venous Thromboembolism
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022 (Issue 1655)
of two direct
oral anticoagulants (DOACs), apixaban (Eliquis) or
rivaroxaban (Xarelto), is often ...
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). US guidelines for
treatment of VTE were updated in 2020 and 2021.
Treatment of Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • Jan 08, 2024 (Issue 1693)
(Eliquis),
and edoxaban (Savaysa) are recommended over the
oral vitamin K antagonist warfarin ...
Atrial fibrillation (AF) is the most common arrhythmia
in the world. Risk factor modification, anticoagulation,
rhythm control, and rate control are the four pillars
of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines
on management of AF were updated recently.
Med Lett Drugs Ther. 2024 Jan 8;66(1693):1-8 doi:10.58347/tml.2024.1693a | Show Introduction Hide Introduction